FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016081804> ?p ?o ?g. }

• W2016081804 endingPage "1669" @default.
• W2016081804 startingPage "1663" @default.
• W2016081804 abstract "BackgroundSeveral randomized phase III studies in advanced stage non-small cell lung cancer (NSCLC) confirmed the superior response rate and progression-free survival of using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor as first-line therapy compared with chemotherapy in patients with activating EGFR mutations. Despite the need for EGFR mutation tests to guide first-line therapy in East Asian NSCLC, there are no current standard clinical and testing protocols.MethodsA consensus meeting was held involving expert oncologists, pulmonologists, and pathologists to discuss the current status and variations in EGFR mutation testing of NSCLC across Asia and to recommend a standard clinical and laboratory testing approach for future use.ResultsCurrently, EGFR mutation tests are only routinely performed in some East Asian countries and medical centers. The consensus recommendation was to perform the test in all newly diagnosed patients with advanced stage nonsquamous lung cancer and some squamous patients with clinical features associated with higher prevalence of EGFR mutations. To increase the sensitivity and specificity of the EGFR mutation tests, tissue acquisition and pretest sample evaluation are important steps in addition to standardization of the EGFR mutation test methodology.ConclusionA standardized EGFR mutation testing protocol is an essential step toward realization of personalized medicine in East Asian NSCLC treatment. Several randomized phase III studies in advanced stage non-small cell lung cancer (NSCLC) confirmed the superior response rate and progression-free survival of using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor as first-line therapy compared with chemotherapy in patients with activating EGFR mutations. Despite the need for EGFR mutation tests to guide first-line therapy in East Asian NSCLC, there are no current standard clinical and testing protocols. A consensus meeting was held involving expert oncologists, pulmonologists, and pathologists to discuss the current status and variations in EGFR mutation testing of NSCLC across Asia and to recommend a standard clinical and laboratory testing approach for future use. Currently, EGFR mutation tests are only routinely performed in some East Asian countries and medical centers. The consensus recommendation was to perform the test in all newly diagnosed patients with advanced stage nonsquamous lung cancer and some squamous patients with clinical features associated with higher prevalence of EGFR mutations. To increase the sensitivity and specificity of the EGFR mutation tests, tissue acquisition and pretest sample evaluation are important steps in addition to standardization of the EGFR mutation test methodology. A standardized EGFR mutation testing protocol is an essential step toward realization of personalized medicine in East Asian NSCLC treatment." @default.
• W2016081804 created "2016-06-24" @default.
• W2016081804 creator A5002458975 @default.
• W2016081804 creator A5003897048 @default.
• W2016081804 creator A5004928583 @default.
• W2016081804 creator A5008578055 @default.
• W2016081804 creator A5020992348 @default.
• W2016081804 creator A5030665179 @default.
• W2016081804 creator A5038637530 @default.
• W2016081804 creator A5045420024 @default.
• W2016081804 creator A5049040142 @default.
• W2016081804 creator A5051731776 @default.
• W2016081804 creator A5052962058 @default.
• W2016081804 creator A5067307453 @default.
• W2016081804 creator A5073362806 @default.
• W2016081804 creator A5086784581 @default.
• W2016081804 creator A5087860798 @default.
• W2016081804 date "2011-10-01" @default.
• W2016081804 modified "2023-10-16" @default.
• W2016081804 title "Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer: A Combined Clinical-Molecular Pathological Approach" @default.
• W2016081804 cites W1969726210 @default.
• W2016081804 cites W1970433797 @default.
• W2016081804 cites W1975627630 @default.
• W2016081804 cites W1979245812 @default.
• W2016081804 cites W1992176720 @default.
• W2016081804 cites W1999719925 @default.
• W2016081804 cites W2009481811 @default.
• W2016081804 cites W2041738335 @default.
• W2016081804 cites W2050368996 @default.
• W2016081804 cites W2069312070 @default.
• W2016081804 cites W2071161965 @default.
• W2016081804 cites W2080951061 @default.
• W2016081804 cites W2089716357 @default.
• W2016081804 cites W2093922887 @default.
• W2016081804 cites W2095618958 @default.
• W2016081804 cites W2101329867 @default.
• W2016081804 cites W2104603750 @default.
• W2016081804 cites W2104748005 @default.
• W2016081804 cites W2105026490 @default.
• W2016081804 cites W2112096254 @default.
• W2016081804 cites W2113244889 @default.
• W2016081804 cites W2120673457 @default.
• W2016081804 cites W2124214040 @default.
• W2016081804 cites W2129360604 @default.
• W2016081804 cites W2130254323 @default.
• W2016081804 cites W2131413118 @default.
• W2016081804 cites W2131831783 @default.
• W2016081804 cites W2132157071 @default.
• W2016081804 cites W2135125731 @default.
• W2016081804 cites W2137853125 @default.
• W2016081804 cites W2139799027 @default.
• W2016081804 cites W2153942353 @default.
• W2016081804 cites W2160040938 @default.
• W2016081804 cites W2165057455 @default.
• W2016081804 cites W2166084034 @default.
• W2016081804 doi "https://doi.org/10.1097/jto.0b013e318227816a" @default.
• W2016081804 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21869714" @default.
• W2016081804 hasPublicationYear "2011" @default.
• W2016081804 type Work @default.
• W2016081804 sameAs 2016081804 @default.
• W2016081804 citedByCount "37" @default.
• W2016081804 countsByYear W20160818042012 @default.
• W2016081804 countsByYear W20160818042013 @default.
• W2016081804 countsByYear W20160818042014 @default.
• W2016081804 countsByYear W20160818042015 @default.
• W2016081804 countsByYear W20160818042016 @default.
• W2016081804 countsByYear W20160818042017 @default.
• W2016081804 countsByYear W20160818042018 @default.
• W2016081804 countsByYear W20160818042019 @default.
• W2016081804 countsByYear W20160818042020 @default.
• W2016081804 countsByYear W20160818042021 @default.
• W2016081804 countsByYear W20160818042022 @default.
• W2016081804 countsByYear W20160818042023 @default.
• W2016081804 crossrefType "journal-article" @default.
• W2016081804 hasAuthorship W2016081804A5002458975 @default.
• W2016081804 hasAuthorship W2016081804A5003897048 @default.
• W2016081804 hasAuthorship W2016081804A5004928583 @default.
• W2016081804 hasAuthorship W2016081804A5008578055 @default.
• W2016081804 hasAuthorship W2016081804A5020992348 @default.
• W2016081804 hasAuthorship W2016081804A5030665179 @default.
• W2016081804 hasAuthorship W2016081804A5038637530 @default.
• W2016081804 hasAuthorship W2016081804A5045420024 @default.
• W2016081804 hasAuthorship W2016081804A5049040142 @default.
• W2016081804 hasAuthorship W2016081804A5051731776 @default.
• W2016081804 hasAuthorship W2016081804A5052962058 @default.
• W2016081804 hasAuthorship W2016081804A5067307453 @default.
• W2016081804 hasAuthorship W2016081804A5073362806 @default.
• W2016081804 hasAuthorship W2016081804A5086784581 @default.
• W2016081804 hasAuthorship W2016081804A5087860798 @default.
• W2016081804 hasBestOaLocation W20160818041 @default.
• W2016081804 hasConcept C121608353 @default.
• W2016081804 hasConcept C126322002 @default.
• W2016081804 hasConcept C143998085 @default.
• W2016081804 hasConcept C2776256026 @default.
• W2016081804 hasConcept C2776694085 @default.
• W2016081804 hasConcept C2777930144 @default.
• W2016081804 hasConcept C2778239845 @default.
• W2016081804 hasConcept C2778820342 @default.

• next